Peter Devine, PhD

Peter has extensive experience at board and executive management levels in venture capital funds management and in the commercialisation of early-stage technologies, having held senior R&D, business development and commercialisation positions in a number of Australian companies and Australian universities.

For the past 20 years, he was CEO of Uniseed, the $200 million partnership between ten leading Australian research institutions and UniSuper. The fund provided a number of high-profile deals including the Fibrotech sale to Shire, the Spinifex sale to Novartis, the Hatchtech sale to Dr Reddy’s Laboratories and Kinoxis Therapeutics license and collaborative researchagreement with Boehringer Ingelheim.  

Prior to this, Peter held positions in four Australian biotechnology companies. He was Vice President of Business Development at ASX-listed Progen Industries which took cancer drug PI-88 into human clinical trials, and was Research, Development and Commercialisation Manager at infectious disease diagnostics company PanBio, which listed on the ASX and was ultimately sold to Inverness Medical.

Peter also had a distinguished career in academic research, being the recipient of a number of competitive grants including two NHMRC grants, which resulted in numerous patents, publications and scientific presentations at conferences.

Peter holds a PhD from the University of Queensland and received the Dean's Prize for his MBA Studies at the Australian Graduate School of Management. He holds a Graduate Diploma in Applied Finance from Kaplan Professional and in 2011 and 2012 was named on the Kaplan High Achievers Honour Roll.

He received a Federal Government Centenary Medal in 2003 for outstanding contribution to the business of biotechnology and in 2018 was named as one of the 5 most influential people worldwide who were changing the face of university venturing (GUV Powerlist 2018).